



## **Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call**

July 28, 2011

PARSIPPANY, N.J., July 28, 2011 /PRNewswire via COMTEX/ --

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that financial results for the company's second quarter ended June 30, 2011 will be released before the market opens on Thursday, Aug. 11, 2011. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, Aug. 11, 2011 at 9 a.m. ET. The call can be accessed by dialing 1-800-884-5695 (domestic) or 1-617-786-2960 (international) and providing the passcode 37821534. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 61411246. The replay will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the company's website at [www.pacira.com](http://www.pacira.com). A replay of the webcast will be archived on the Pacira website for two weeks following the call.

### **About Pacira**

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postsurgical analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at [www.pacira.com](http://www.pacira.com).

### **Contacts:**

James S. Scibetta  
Chief Financial Officer  
Pacira Pharmaceuticals, Inc.  
(973) 254-3570

Jennifer Beugelmans  
Vice President, Investor Relations  
Pure Communications, Inc.  
(646) 596-7473

SOURCE Pacira Pharmaceuticals, Inc.